

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 40, Number 1, January 2020

Contents

Review

- Current Treatment of Colorectal Liver Metastasis as a Chronic Disease. N.M. DÖRR, M. BARTELS, M.H. MORGUL (*Leipzig; Münster, Germany*)..... 1

Experimental Studies

- SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2. K.L. STEED, H.R. JORDAN, T.O. TOLLEFSBOL (*Birmingham, AL, USA*) 9
- Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans. M. ABBAS, T. MASON, A. IBAD, M. KHRAIWESH, V. APPREY, Y. KANAAN, B. WILSON, G. DUNSTON, L. RICKS-SANTI, H. BRIM (*Washington, DC; Silver Spring, MD; Hampton, VA, USA*)..... 27
- High Expression of *c-Met*, *PKC λ* and *ALDH1A3* Predicts a Poor Prognosis in Late-stage Breast Cancer. H. MOTOMURA, Y. NOZAKI, C. ONAGA, A. OZAKI, S. TAMORI, T.-A. SHIINA, S. KANAI, C. OHIRA, Y. HARA, Y. HARADA, R. TAKASAWA, T. HANAWA, S.-I. TANUMA, Y. MANO, T. SATO, K. SATO, K. AKIMOTO (*Chiba, Japan*)..... 35
- Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines. S. HOLZHAUSER, M. LUKOSEVICIUTE, T. ANDONOVA, R.G. URSU, T. DALIANIS, M. WICKSTRÖM, O.N. KOSTOPOULOU (*Stockholm, Sweden; Iasi, Romania*) 53
- Cisplatin Induced the Expression of *SEI1 (TRIP-Br1)* Oncogene in Human Oral Squamous Cancer Cell Lines. J. LI, Z. VANGUNDY, M. POI (*Columbus, OH, USA*)..... 67

Contents continued on the back cover

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005
ISSN (online): 1791-7530

Editorial Board

- P. A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, San Diego, CA, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
P. Z. ANASTASIADIS, Jacksonville, FL, USA
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
D.-T. BAU, Taichung, Taiwan, ROC
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
M. BOUVET, La Jolla, CA, USA
J. BOYD, Miami, FL, USA
G. BROICH, Monza, Italy
Ø. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
R. CLARKE, Washington, DC, USA
E. DE CLERCQ, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
L. EGEVAD, Stockholm, Sweden
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
H. FU, Atlanta, GA, USA
B. FUCHS, Zurich, Switzerland
D. FUCHS, Innsbruck, Austria
D. FUKUMURA, Boston, MA, USA
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
M. GNANT, Vienna, Austria
R. H. GOLDFARB, Guilford, CT, USA
A. HELLAND, Oslo, Norway
L. HELSON, Quakertown, PA, USA
R. HENRIKSSON, Umeå, Sweden
R. M. HOFFMAN, San Diego, CA, USA
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
R. JONES, London, UK
B. KAINA, Mainz, Germany
P. -I. KELLOKUMPU-LEHTINEN, Tampere, Finland
D. G. KIEBACK, Schleswig, Germany
R. KLAPDOR, Hamburg, Germany
H. KOBAYASHI, Bethesda, MD, USA
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Manchester, UK
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
S. LINDER, Linköping, Sweden
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. S. MARTIN, Baltimore, MD, USA
S. MITRA, Houston, TX, USA
S. MIYAMOTO, Fukuoka, Japan
S. MONCADA, Manchester, UK
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGIA, New York, NY, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J.L. PERSSON, Malmö, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUKAS, Norfolk, VA, USA
A. POLLIACK, Jerusalem, Israel
D. RADES, Lübeck, Germany
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
S.T. ROSEN, Duarte, CA, USA
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
J. SEHOULI, Berlin, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
A. SLOMINSKI, Birmingham, AL, USA
G.-I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
J. WESTERMARCK, Turku, Finland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Taipei, Taiwan, ROC
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA
G. J. DELINASIOS, Athens, Greece
Managing Editor and
Executive Publisher
J. G. DELINASIOS, Athens, Greece
Managing Editor (1981-2016)

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IAR is a member of UICC. For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: www.iia-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2020 per volume: Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-39, 1981-2019) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iia-anticancer.org)

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Biosis Previews, Essential Science Indicators, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABs, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2020, International Institute of Anticancer Research

(Dr. George J. Delinasios), All rights reserved.

D.T.P. BY IIA

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 40

2020

Editorial Board

P. A. Abrahamsson	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
B. B. Aggarwal	Director, Inflammation Research Center, San Diego, CA, USA
T. Akimoto	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
P. Z. Anastasiadis	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
A. Argiris	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
J. P. Armand	Institut Claudius Regaud, Toulouse, France
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
D.-T. Bau	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
M. Bouvet	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
J. Boyd	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
G. Broich	Gruppo Policlinico di Monza, Monza, Italy
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
J. M. Buatti	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
C. Carlberg	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
R. Clarke	Georgetown University Medical Center, Washington, DC, USA
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
L. Egevad	Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
D. W. Felsher	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
A. P. Fields	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
H. Fu	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
B. Fuchs	Balgrist University Hospital, Zurich, Switzerland
D. Fuchs	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria
D. Fukumura	Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA

G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
R. Ganapathi	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
M. Gnant	Department of Surgery, Medical University of Vienna, Austria
R. H. Goldfarb	R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
A. Helland	Oslo University Hospital-Radium Hospital, Oslo, Norway
L. Helson	Sign Path Pharma, Inc., Quakertown, PA, USA
R. Henriksson	Department of Experimental Oncology, Umeå University, Umeå, Sweden
R. M. Hoffman	Department of Surgery, University of California, San Diego, CA, USA
S. C. Jhanwar	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. V. Johannessen	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
R. Jones	Sarcoma Unit, Royal Marsden Hospital, London, UK
B. Kaina	Institute of Toxicology, University of Mainz, Germany
P. -L. Kellokumpu-Lehtinen	Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
D. G. Kieback	Helios Medical Center Schleswig, Schleswig, Germany
R. Klapdor	Medical Clinic, University of Hamburg, Germany
H. Kobayashi	Laboratory of Molecular Theranostics, NCI/NIH, Bethesda, MD, USA
S. D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
Pat M. Kumar	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar	Department Pathology, University of Manchester Medical School, Manchester, UK
O. D. Laerum	Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
S. Linder	Department of Medicine and Health, Linköping University, Linköping, Sweden
L. F. Liu	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren	Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
Y. Maehara	Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
J. Maher	Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
J. Marescaux	IRCAD, University of Strasbourg, France
J. Mark	Department of Pathology, Kärnshuset, Skövde, Sweden
S. S. Martin	Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
S. Mitra	The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
S. Miyamoto	Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
S. Moncada	Manchester Cancer Research Centre, University of Manchester, Manchester, UK
M. Mueller	Hochschule Furtwangen University, Villingen-Schwenningen, Germany
F. M. Muggia	New York University Cancer Institute, School of Medicine, NY, USA

- M. Namiki** Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
- R. Narayanan** Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
- K. Nilsson** Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
- S. Pathak** Department of Cell Biology, University of Texas, Houston, TX, USA
- J. L. Persson** Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- D. Rades** Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
- M. Rigaud** Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
- M. Roselli** Department of Medical Oncology, University of Rome "Tor Vergata", Italy
- S.T. Rosen** Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
- A. Schauer** Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
- M. Schneider** Department of Organic Chemistry, Bergische University, Wuppertal, Germany
- J. Sehouli** Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
- A. Seth** Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
- G. V. Sherbet** Cancer Research Unit, University of Newcastle-upon-Tyne, UK
- A. Slominski** Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
- G.-I. Soma** Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
- G. S. Stein** Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
- T. Stigbrand** Department of Immunology, Umeå University, Umeå, Sweden
- T. M. Theophanides** Department of Chemistry, Technical University of Athens, Greece
- P. M. Ueland** Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
- H. Van Vlierberghe** Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
- R.G. Vile** Department of Immunology, Mayo Clinic, Rochester, MN, USA
- M. Weller** Department of Neurology, University Hospital Zurich, Zurich, Switzerland
- J. Westermarck** Centre for Biotechnology, University of Turku, Turku, Finland
- B. Westermarck** Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
- Y. Yen** Taipei Medical University, Taipei, Taiwan, ROC
- M. R. I. Young** Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
- B. Zumoff** Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The IAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 39, 2019.

- AbbVie Pharmaceuticals, Lake Bluff, IL, U.S.A.
 Academy of Finland, Helsinki, Finland
 Adaptable and Seamless Technology Transfer Program through Target-driven R&D, Japan Science and Technology Agency (JST), Kawaguchi, Japan
 Adlerbertska Foundation, Gothenburg, Sweden
 Advanced Medical Services (AMS) GmbH, Mannheim, Germany
 Agenus Inc., Lexington, MA, U.S.A.
 AIL La Spezia - Sezione "Francesca Lanzone", La Spezia, Italy
 Ajou Human Bio-Resource Bank (AHBB), Ajou University Hospital, Suwon, Republic of Korea
 Ajou University School of Medicine, Suwon, Republic of Korea
 American Cancer Society, Atlanta, GA, U.S.A.
 Amgen Chair for Therapeutic Advances in Ovarian Cancer
 Anapole Technologies, Inc., Burlington, IA, U.S.A.
 Anelise-Asmussen-Stiftung, Luebeck, Germany
 Asan Institute for Life Sciences, Seoul, Republic of Korea
 Asia University, Taichung, Taiwan, R.O.C.
 Assar Gabriellson Foundation, Gothenburg, Sweden
 Association pour la Recherche sur les Tumeurs Cérébrales (ARTC) Sud, Marseille, France
 Associazione Amici Istituto del Radio Olindo Alberti, Brescia, Italy
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy
 AstraZeneca plc, Cambridge, U.K.
 AstraZeneca, Athens, Greece
- Basic Medical Experimental Teaching Center, Jilin University, Changchun, P.R. China
 Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Science and ICT, Gwacheon, Republic of Korea
 BIO & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
 Biohit Oyj, Helsinki, Finland
 Bio-Manguinhos/FIOCRUZ, Rio de Janeiro, Brazil
 Biomedical Center Martin, Jessenius Faculty of Medicine, Martin Comenius University, Bratislava, Slovak Republic
 Biomedical Research Centre (BRC), U.K.
 Biomedicine Centre of the Academy of Sciences and Charles University in Vestec (BIOCEV), Prague, Czech Republic
 Bio-oriented Technology Research Advancement Institution (BRAIN), National Agriculture and Food Research Organization (NARO), Japan
 Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University, Vestec, Czech Republic
 Biotechnology Division, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, Greece
 BK21 PLUS Program for Creative Veterinary Science, Seoul National University, Seoul, Republic of Korea
 Breast Cancer Hope Foundation, London, U.K.
 Breast European Adjuvant Studies Team (BrEAST), Brussels, Belgium
 Breast International Group (BIG), F. Hoffmann-La Roche, Ltd., Basel, Switzerland
 Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.
 BTX, Wroclaw, Poland
 Bulgarian National Scientific Program "Young Scientists and Postdoctoral Students", Bulgaria
- Canadian Institutes of Health Research (CIHR), Ottawa, ON, Canada
 Cancer Center, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C.
 Cancer Chemotherapy Center, Osaka Medical College, Takatsuki, Japan
 Cancer Foundation Finland, Helsinki, Finland
 Cancer Prevention Institute of Texas, Austin, TX, U.S.A.
 Cancer Registry, Office of Medical Records, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
 Cancer Research Center, University at Albany (SUNY), Rensselaer, NY, U.S.A.
 Cancer Research Funds for Patients and Family, Medical Welfare Network Chiba (MWNC-NPO), Chiba, Japan
 Cancer Research Funds, Radiumhemmet, Solna, Sweden
 Cancer Research UK (CRUK), Oxford, U.K.
 Cancer Society, Stockholm, Sweden
 Cancer Treatment Research Trust UK (CTRT), Northwood, U.K.
 CCA Foundation, the Netherlands

- Cell-Based Drug and Health Products Development
Research Unit, Chulalongkorn University, Bangkok,
Thailand
- Center for Drug Delivery Research, Tokyo University of
Science, Tokyo, Japan
- Center for Individualized Medicine, Mayo Clinic,
Jacksonville, FL, U.S.A.
- Center for Teaching and Learning, Thomas Jefferson
University, Philadelphia, PA, U.S.A.
- Centers of Genomic and Precision Medicine, National
Taiwan University, Taipei, Taiwan, R.O.C.
- Centre de Recherches en Nutrition Humaine (CRNH)
d'Auvergne, Clermont-Ferrand, France
- Centro de Investigación Biomédica en Red en Diabetes y
Enfermedades Metabólicas asociadas (CIBER-DEM),
Madrid, Spain
- Centro Médico Antroposófico (CMA), Lima, Peru
- Chang Bing Show Chwan Memorial Hospital, Changhua,
Taiwan, R.O.C.
- Chang Gung Memorial Hospital, Chiayi City, Taiwan, R.O.C.
- Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
- Charles University Research Center, Prague, Czech
Republic
- Charles University Research Fund (PROGRES), Charles
University in Prague, Prague, Czech Republic
- Charles University, Prague, Czech Republic
- Chi-Mei Medical Center, Tainan City, Taiwan, R.O.C.
- China Medical University Hospital, Taichung, Taiwan,
R.O.C.
- China Medical University, Taichung, Taiwan, R.O.C.
- China Post-doctoral Research Fund
- Chinese Scholarship Council, Beijing, P.R. China
- Chosun University Dental Hospital, Dong-gu, Republic of
Korea
- Chosun University, Gwangju, Republic of Korea
- Christophorus Stiftung, Stuttgart, Germany
- Chugai Pharmaceutical Co., Ltd, Tokyo, Japan
- Chulabhorn Graduate Institute, Bangkok, Thailand
- Chulabhorn Research Institute, Bangkok, Thailand
- Chulalongkorn University, Bangkok, Thailand
- Chungnam National University Hospital Research Fund,
Daejeon, Republic of Korea
- CLEA Japan, Inc., Tokyo, Japan
- Clinical Rebiopsy Bank Project for Comprehensive Cancer
Therapy Development, Nippon Medical School, Tokyo,
Japan
- Clinical Research Facility in Imaging, Bristol, U.K.
- College of Pharmacy, The Ohio State University,
Columbus, OH, U.S.A.
- Comitato Assistenza Malati e Lotta Contro i Tumori,
Sarzana, Italy
- Commission on Cancer, American College of Surgeons,
Chicago, IL, U.S.A.
- Conceptual Development of Research Organization,
University Hospital in Pilsen-FNPI, Pilsen, Czech
Republic
- Connecticut Innovations, Rocky Hill, CT, U.S.A.
- Consejo Nacional De Ciencia y Tecnología (CONACyT),
Mexico City, Mexico
- Consejo Superior de Investigaciones Científicas (CSIC),
Madrid, Spain
- Conselho Nacional de Desenvolvimento Científico e
Tecnológico (CNPq), Brasilia, Brazil
- Convergence mEDicine research cenTer (CREDIT), Asan
Institute for Life Sciences, Asan Medical Center, Seoul,
Republic of Korea.
- Cooperative Research Program for Agriculture Science
and Technology Development, Rural Development
Administration, Republic of Korea
- Coordenação de Aperfeiçoamento de Pessoal de Nível
Superior (CAPES), Brasilia, Brazil
- Core Research for Evolutional Science and Technology
(CREST), Tokyo, Japan
- Council for Science, Technology and Innovation (CSTI),
Tokyo, Japan
- Creative Educational Concepts (CEC), Inc., Lexington,
KY, U.S.A.
- Croatian Science Foundation, Ministry of Science and
Education, Zagreb, Republic of Croatia
- Cross-ministerial Strategic Innovation Promotion Program
(SIP), Japan
- Czech Science Foundation, Prague, Czech Republic
- D.I.P. Co., Ltd., Gunma, Japan
- Danish Cancer Society, Copenhagen, Denmark
- Deanship of Scientific Research (DSR), King Abdulaziz
University, Jeddah, Kingdom of Saudi Arabia
- Department of Anatomic Pathology, Kyushu University,
Fukuoka, Japan
- Department of Biochemistry and Molecular Biology,
Faculty of Veterinary Medicine, Wrocław University of
Environmental and Life Sciences, Wrocław, Poland
- Department of Breast and Endocrine Surgery, Osaka City
University Graduate School of Medicine, Osaka, Japan
- Department of Defense (DoD), Arlington County, VA, U.S.A.
- Department of Dermatology and Dermatologic Surgery,
Medical University of South Carolina, Charleston, SC,
U.S.A.

- Department of Diagnostic and Interventional Radiology, Osaka University Hospital, Suita, Japan
- Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan
- Department of English, Tokyo Medical University, Tokyo, Japan
- Department of General and Gastroenterological Surgery, Osaka Medical University, Osaka, Japan
- Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- Department of General Thoracic Surgery, Tokai University Hachioji Hospital, Hachioji, Japan
- Department of Health, U.K.
- Department of Human Lifesciences, School of Nursing, Fukushima Medical University, Fukushima, Japan
- Department of Human Pathology, University of Yamanashi, Kofu, Japan
- Department of Medical Education of Tokyo Medical University, Tokyo, Japan
- Department of Medical Microbiology and Clinical Pathology, Laboratory Medicine, Region Skåne, Lund, Sweden
- Department of Medical Research, National Taiwan University Hospital (NTUH), Taipei City, Taiwan, R.O.C.
- Department of Neurosurgery, Graduate School of Medicine, Osaka City University, Osaka, Japan
- Department of Neurosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan
- Department of Orthopedic and Trauma Surgery, Ortho-Klinik Dortmund, Dortmund, Germany
- Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
- Department of Pathology, Teikyo University School of Medicine, Tokyo, Japan
- Department of Pediatrics, Gifu University, Gifu, Japan
- Department of Pharmacy, Gifu University Hospital, Gifu, Japan
- Department of Radiation Effects Research, National Institute of Radiological Sciences (NIRS), Chiba, Japan
- Department of Radiation Oncology, Gunma University Graduate School of Medicine.
- Department of Radiology, Tokai University School of Medicine Included Hachioji Hospital, Hachioji, Japan
- Department of Science and Technology (DST), New Delhi, India
- Department of Surgery, Institute of Health Biosciences, University of Tokushima, Tokushima, Japan
- Department of Urology, District Hospital, Bad-Hersfeld, Germany
- Department of Urology, Radcliffe Hospital, Cambridge, U.K.
- Department of Urology, University of Heidelberg, Heidelberg, Germany
- Departments of Medical Oncology and Head and Neck Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
- Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute, Bethesda, MD, U.S.A.
- Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan, R.O.C.
- Division of Clinical Pathology, Sant'Andrea Hospital, La Spezia, Italy
- Division of Medical Oncology Cancer Research Institute, Kanazawa University, Kanazawa, Japan
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Tottori, Japan
- Division of Pneumology, San Bartolomeo Hospital, Sarzana, Italy
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- Dutch Cancer Society (DCS) - KWF Kankerbestrijding, Amsterdam, the Netherlands
- Dynamic Science, Barcelona, Spain
- EA Pharma Co., Ltd., Tokyo, Japan.
- Economic Development and Innovation Operative Programme (GINOP), Hungary
- E-Da Hospital, Kaohsiung, Taiwan, R.O.C.
- Education Research Fund, Tokyo University of Science, Tokyo, Japan
- Eisai, Inc., Tokyo, Japan
- ELPEN Pharmaceutical Co., Inc., Athens, Greece
- Ethics Committee of Kobe City Medical Center General Hospital, Kobe, Japan
- ETHICS project, National Institute for Nuclear Physics (INFN), Italy
- European MRI and Rectal Cancer Surgery (EuMaRCS) Study Group

- European Organisation for Research and Treatment of Cancer (EORTC)- Pharmacology and Molecular Mechanisms (PAMM) Group, Brussels, Belgium
- European Regional Development Fund (ERDF), Brussels, Belgium
- European Regional Development Fund-Project “Application of Modern Technologies in Medicine and Industry”, Brussels, Belgium
- European Union Seventh Framework Programme, European Commission, Brussels, Belgium
- EVO Funds, Kuopio University Hospital, Kuopio, Finland
- EVO-funding, Helsinki University Hospital, Helsinki, Finland
- Excellent Research Laboratory, Cancer Molecular Biology and Research Center for Cancer Control, Thailand
- Excellus BCBS, Rochester, NY, U.S.A.
- Experimental, Educational and Research Center ELPEN, Pikermi, Greece
- Extreme Light Infrastructure (ELI)- Attosecond Light Pulse Source (ALPS), Szeged, Hungary
- Faculty of Medicine, Songkhla, Thailand
- Featured Areas Research Center Program, Higher Education Sprout Project, Ministry of Education (MOE), Taipei, Taiwan, R.O.C.
- Financial Grant, China Postdoctoral Science Foundation (GRID), Beijing, P.R. China
- Finnish Cancer Foundation, Helsinki, Finland
- Finnish Cancer Society, Helsinki, Finland
- Finnish Medical Foundation, Helsinki, Finland
- Finnish Medical Society Duodecim, Helsinki, Finland
- Finnish Society of Oncology, Helsinki, Finland
- Finnish State Research Funding, Helsinki, Finland
- Finnish Work Environment Fund, Helsinki, Finland
- Flemish Cancer Society, Belgium
- Florida Wine and Grape Growers Association, St. Augustine Beach, FL, U.S.A.
- Fondazione Pisana per la Scienza, San Giuliano Terme, Italy
- Fondo para el Fortalecimiento de la Investigacion (FOFI) - Universidad Autonoma de Queretaro (UAC), Querétaro, Mexico
- FORSS-Medical Research Council of Southeast Sweden, Linköping, Sweden
- Foundation for Clinical Cancer Research in Jönköping, Jönköping, Sweden
- Fred Hutchinson Cancer Research Center, Seattle, WA, U.S.A.
- Friedrich-Baur-Foundation, Altenkunstadt, Germany
- Fujian Provincial Health Department Young and Middle-aged Talents Training Project, P.R. China
- Fujian Provincial Natural Science Foundation, P.R. China
- Fund for Shanxi Key Subjects Construction (FSKSC), Natural Science Foundation of Shanxi Province, Taiyuan, P.R. China
- Fund for the Promotion of Science, School of Medicine, Keio University, Tokyo, Japan
- Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Ipatinga, Brazil
- Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal
- Fundación Bancaria “La Caixa”, Valencia, Spain
- Fundación Caja Navarra, Pamplona, Spain
- Funding Project of Jiangsu Province, Jiangsu, P.R. China
- Fundo Europeu de Desenvolvimento Regional (FEDER), Lisbon, Portugal
- Futurum, Academy for Health and Care, Jönköping, Sweden
- General Directorate for Scientific Research and Technological Development (DGRSDT), Algeria
- Genome Korea Project in Ulsan Research Fund, UNIST, Republic of Korea
- Genomics & Proteomics Core Library, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan R.O.C.
- Georg-August University Göttingen, Göttingen, Germany
- German Academic Exchange Service (DAAD), New York, NY, U.S.A.
- GlaxoSmithKline Biologicals SA, Rixensart, Belgium
- GlaxoSmithKline Oy, Espoo, Finland
- GlaxoSmithKline, Brentford, U.K.
- Global COE Program for Metabolomics Systems Biology, Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan
- Göteborg Dental Society, Göteborg, Sweden
- Gout Research Foundation of Japan, Tokyo, Japan
- Grand Forks Human Nutrition Research Center, Washington, DC, U.S.A.
- Grant Agency of Ministry of the Education, Science, Research and Sport of the Slovak Republic, Bratislava, Slovak Republic
- Grant Agency of the Czech Republic, Prague, Czech Republic
- Grant for International Research Integration, Chula Research Scholar, Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand
- Grant-in-Aid Encouragement of Scientists Research Fund, Saitama Prefectural University, Koshigaya, Japan

- Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
- Grants-in-Aid for Scientific Research, for Challenging Exploratory Research, and for Young Scientists, Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan
- Grants-in-Aid for Young Scientists, Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan
- Guangdong Science and Technology Department, Guangzhou, P.R. China
- Gunma University Heavy-Ion Medical Center (GHMC), Maebashi, Japan
- Gunma University Hospital, Maebashi, Japan
- Hallym University Research Fun, Chuncheon, Republic of Korea
- Harasanshin Hospital, Fukuoka, Japan
- Health and Welfare Data Science Center, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- Health Research Board of Ireland, Dublin, Republic of Ireland
- Healthcare Board, Region Västra Götaland (Hälsa-och sjukvårdsstyrelsen), Sweden
- Heikki, Aino and Aarne Korhonen Foundation, Finland
- Heilongjiang Bayi Agricultural University, Daqing, P.R. China
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
- Hellenic Society for Medical Oncology (HeSMO), Athens, Greece
- Hellenic Thoracic Society Research Award, Athens, Greece
- Heriot-Watt University (HWU) Start-up Fund (MIP), Edinburgh, U.K.
- Histology Section, Tissue Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
- HLB Life Science Co., Ltd., Seongnam, Republic of Korea
- Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, SC, U.S.A.
- Howard University, Washington, DC, U.S.A.
- Hyogo College of Medicine, Nishinomiya, Japan
- INCLIVA Instituto de Investigación Sanitaria, Valencia, Spain
- Innosuisse, Bern, Switzerland
- Institute of Pathology, University of Ljubljana, Ljubljana, Slovenia
- Institut für Hämatopathologie Kiel, Kiel, Germany
- Institute of Cytology and Genetics, Novosibirsk, Russian Federation
- Institute of Medical Biometry, Informatics, and Epidemiology (IMBIE), University of Bonn Medical School, Bonn, Germany
- Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
- Instituto de Investigación de Citopatología (CITOPAT), Lima, Peru
- Instituto de Radioproteção e Dosimetria (IRD)/ Comissão Nacional de Energia Nuclear (CNEN), Rio de Janeiro, Brasil
- Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- International Cooperation Project, P.R. China
- Interreg Deutschland-Danmark Programme, Kruså, Denmark
- Inui Immunotherapy Clinic, Osaka, Japan
- Investment-linked Corporate Growth R&D Support Program, Korea Industrial Technology Association, Republic of Korea
- Iowa Science Foundation Grant, Cedar Falls, IA, U.S.A.
- Italian Ministry of Education, University and Research (MIUR), Rome, Italy
- Italian Ministry of Health, Rome, Italy
- Jan Kochanowski University, Kielce, Poland
- Jane and Aatos Erkkö Foundation, Helsinki, Finland
- János Bolyai Scholarship, Hungarian Academy of Sciences, Budapest, Hungary
- Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Japan Community Healthcare Organization (JCHO) Kyushu Hospital, Kitakyushu, Japan
- Japan Orthopedics and Traumatology Research Foundation, Inc., Tokyo, Japan
- Japan Science and Technology Agency (JST), Tokyo, Japan
- Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
- Japan Society of Clinical Oncology (JSCO), Tokyo, Japan
- Japanese Foundation for Research and Promotion of Endoscopy Grant (JFE), Tokyo, Japan
- Jefferson College of Pharmacy (JCP), Philadelphia, PA, U.S.A.
- Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, P.R. China
- Jikei University School of Medicine, Tokyo, Japan
- John Curtin School of Medical Research, Australian National University, Canberra, Australia
- John Dick Lab of Princess Margaret Cancer Centre, Toronto, ON, Canada

- Joint European Resources for Micro to Medium Enterprises (JEREMIE), European Union
- Joint Funds for the Innovation of Science and Technology, Fujian Province, P.R. China
- Joint Research Foundation of Region of Zealand and Region of Southern Denmark
- Jönköping Clinical Cancer Research Foundation, Jönköping, Sweden
- Kagoshima University, Kagoshima, Japan
- Kanagawa Standard Anti-cancer Therapy Support System (KSATSS), Kanagawa, Japan
- Kaohsiung Medical University Research Foundation, Kaohsiung, Taiwan R.O.C.
- Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, R.O.C.
- Keelung Chang Gung Medical Center Intramural Grant, Keelung, Republic of Korea
- Key Disciplines of Jiangsu Provincial Department of Health, P.R. China
- Key Laboratory of Malignant Tumour Gene Regulation and Target Therapy, Guangdong Higher Education Institutes, Guangzhou, P.R. China
- Key Laboratory of Malignant Tumour Molecular Mechanism and Translational Medicine, Guangzhou Bureau of Science and Information Technology, Guangzhou, P.R. China
- Key Laboratory of Pathology and Biology Teaching, Ministry of Education, Beijing, P.R. China
- Khon Kaen University, Khon Kaen, Thailand
- Kindai University, Higashi-osaka, Japan
- Kitakyushu Municipal Medical Center, Kitakyushu, Japan
- Kitasato University Medical Center, Kitamoto, Japan
- Kitasato University Research Grant for Young Researchers, Kitamoto, Japan
- Kobayashi Foundation for Cancer Research, Tokyo, Japan
- Köln Fortune, Köln, Germany
- Kom Op Tegen Kanker (Stand up to Cancer), Belgium
- Kongju National University, Gongju, Republic of Korea
- Korea Health Technology R&D Project, Korean Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea
- Korea Institute of Radiological and Medical Sciences (KIRAMS), Ministry of Science, ICT and Future Planning (MSIP), Gwacheon, Republic of Korea
- Korea Research Foundation, Republic of Korea
- Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
- Korean Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET), Agri-Bio Industry Technology Development Program, Ministry of Agriculture, Food and Rural Affairs (MAFRA), Republic of Korea
- Korean Society of Gastrointestinal Cancer, Seoul, Republic of Korea
- Korean Society of Pathologists Grant, Seoul, Republic of Korea
- Kowa Company, Ltd., Nagoya, Japan
- Kuopio University Hospital Research Funding, Kuopio, Finland
- Kuopio University Hospital, Kuopio, Finland
- Kyorin University, Mitaka, Japan
- Kyoto Pharmaceutical University, Kyoto, Japan
- Kyoto Prefectural University of Medicine (KPU) Fund for the Promotion of Collaborative Research, Kyoto, Japan
- Kyung Hee University, Seoul, Republic of Korea
- Kyungpook National University, Daegu, Republic of Korea
- Kyushu Central Hospital, Fukuoka, Japan
- Laboratory for Clinical Investigation, Osaka University Hospital, Osaka, Japan
- Laboratory of Molecular Biochemistry, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
- Laserlab-Europe, Berlin, Germany
- Latvian Institute of Organic Synthesis, Riga, Latvia
- Leading Graduate Schools, Cultivating Global Leaders in Heavy Ion Therapeutics and Engineering, Gunma University, Maebashi, Japan
- Leading University as a Base for Human Resource Development in Nanoscience and Nanotechnology, Osaka Prefecture University, Osaka, Japan
- Leibniz Institute of Plant Biochemistry (IPB), Halle, Germany
- LEO Pharma GmbH, Neu-Isenburg, Germany
- LLP Erasmus Program, Paris, France
- Mackay Medical College, New Taipei City, Taiwan, R.O.C.
- Magellan Scholar Award, University of South Carolina, Columbia, SC, U.S.A.
- Management Expenses Grant, Ministry of Education, Culture, Sports, Science and Technology, Japan
- Massachusetts College of Pharmacy and Health Science (MCPHS), Boston, MA, U.S.A.
- Mayo Clinic Center for Individualized Medicine, Rochester, MN, U.S.A.

- Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, U.S.A.
- Medical Faculty, Ruhr University Bochum, Bochum, Germany
- Medical Faculty, University of Pecs, Hungary
- Medical Faculty, University of Pecs, Pecs, Hungary
- Medical Research Core Facilities Center, Office of Research & Development, China Medical University, Taichung, Taiwan, R.O.C.
- Medical University of Gdansk, Gdansk, Poland
- Medical University of Lublin, Lublin, Poland
- Mediterranean Cancer Support and Rehabilitation – Medicare Onlus, Catania, Italy
- Meditrix Corporation, Tokyo, Japan
- MedStar Health Research Institute (MHRI), Hyattsville, MS, U.S.A.
- Meikai University School of Dentistry, Sakado, Japan
- Mercer University, Macon, GA, U.S.A.
- Ministry of Science and Culture of Lower Saxony (Niedersächsischen Ministerium für Wissenschaft und Kultur), Hanover, Germany
- Ministry of Aliyah and Immigrant Absorption, Tel Aviv, Israel
- Ministry of Education (MOE), Taipei, Taiwan, R.O.C.
- Ministry of Education and Research, Stockholm, Sweden
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
- Ministry of Education, Youth and Sports, Prague, Czech Republic
- Ministry of Education, Science and Technological Development, Belgrade, Serbia
- Ministry of Education, Science, Research, and Sport, Bratislava, Slovak Republic
- Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- Ministry of Health of the Czech Republic, Prague, Czech Republic
- Ministry of Health, Labor and Welfare of Japan, Tokyo, Japan
- Ministry of Higher Education and Scientific Research (MOHESR), Baghdad, Iraq
- Ministry of Human Capacities, Budapest, Hungary
- Ministry of Science and Higher Education of Poland, Warsaw, Poland
- Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea
- Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
- Ministry of Science and Technology, Bangkok, Thailand
- Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea
- Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
- Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan
- Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan
- Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, U.S.A.
- Molecular Unit, Department of Pathology, Herlev Hospital, Herlev, Denmark
- Multidisciplinary Research Theme (MDRT) in Bio-economy, Northumbria University, Newcastle Upon Tyne, U.K.
- NAHLS. Co., Ltd, Kyoto, Japan
- Naito Foundation, Tokyo, Japan
- National Biobank of Korea, Ministry of Health and Welfare, Seoul, Republic of Korea
- National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
- National Clinical Key Specialty Construction Project (General Surgery), P.R. China
- National Committee for Scientific Research, Poland
- National Health and Medical Research Council of Australia
- National Health Insurance Research Database, Bureau of National Health Insurance, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- National Health Research Institutes, Taipei, Taiwan R.O.C.
- National Health Service, U.K.
- National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, U.S.A.
- National Institute for Agricultural Research (INRA), France
- National Institute for General Medical Science (NIGMS), National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A.
- National Institute for Health Research (NIHR) Royal Marsden (RM) Institute of Cancer Research (ICR) Biomedical Research Centre, London, U.K.
- National Institute of Health Sciences (NIHS), Kawasaki, Japan
- National Institute of Minority Health and Health Disparities (NIMHD), NIH, Bethesda, MD, U.S.A.
- National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

- National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A.
- National Key Research and Development Program of China, Beijing, P.R. China
- National Natural Science Foundation of China, Guangdong, P.R. China
- National R&D Program for Cancer Control, Ministry of Health and Welfare, Seoul, Republic of Korea
- National Research Council of Argentina (CONICET), Buenos Aires, Argentina
- National Research Foundation of Korea (NRF), Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea
- National Science Centre (NCN), Warsaw, Poland
- National Science Council, Taiwan, R.O.C.
- National Sustainability Program I (NPU I), Ministry of Education Youth and Sports, Prague, Czech Republic
- National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
- National Tsing Hua University, Hsinchu, Taiwan, R.O.C.
- National Yang Ming University, Taipei, Taiwan, R.O.C.
- Natural Science Foundation of China, P.R. China
- Neurographie Nord, Hamburg, Germany
- Nihon University Academic Research Grant, Tokyo, Japan
- Nihon University Multidisciplinary Research Grants, Tokyo, Japan
- Nihon University School of Medicine Itabashi Hospital, Tokyo, Japan
- Nippon Boehringer Ingelheim Co., Tokyo, Japan
- Nitto Foundation, Osaka, Japan
- North Savo Regional Fund, Finnish Cultural Foundation, Helsinki, Finland
- Novartis Pharma K.K., Tokyo, Japan
- Novartis, Basel, Switzerland
- Novelpharm AG, Schlieren, Switzerland
- Novosibirsk State University, Novosibirsk, Russian Federation
- Office of Science and Technology (OSTC), Royal Thai Embassy, Brussels, Belgium
- Ohio State University, Columbus, OH, U.S.A.
- Olivia Fund, Belgium
- Open Chemical Repository, Developmental Therapeutics Program (DTP), National Cancer Institute (NCI), Bethesda, MD, U.S.A.
- Operational Program Research, Development and Education, Prague, Czech Republic
- Operational Programme Research and Innovation, European Regional Development Fund (ERDF), Brussels, Belgium
- Osaka City University Graduate School of Medicine, Osaka, Japan
- Osaka Foundation for Promotion of Fundamental Medical Research, Osaka, Japan
- Osaka Foundation for the Prevention of Cancer and Cardiovascular Diseases, Osaka, Japan
- Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG), Osaka, Japan
- Osaka Medical College Cancer Medical Center, Osaka, Japan
- Osaka National Hospital (ONH), Osaka, Japan
- Osaka Prefecture University, Osaka, Japan
- Oxford PharmaGenesis, Inc., Newtown, PA, U.S.A.
- Pelotonia IDEA Award, Columbus, OH, U.S.A.
- Pfizer Inc., New York, NY, U.S.A.
- Pfizer Oy, Helsinki, Finland
- Pirkanmaa Cancer Foundation, Tampere, Finland
- Pirkanmaa Hospital District's Science Centre, Tampere, Finland
- Polish Ministry of Science and Higher Education, Warsaw, Poland
- Polistudium srl, Milan, Italy
- Prince of Songkla University (PSU), Hat Yai, Thailand
- Priority Academic Program Development of Jiangsu Higher Education Institution (PAPD), P.R. China
- Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT) - Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
- Programa de Educação Tutorial (PET), Secretaria de Educação Superior do Ministério da Educação (SESu/MEC), Brazil
- Programa Operacional Competitividade e Internacionalização (POCI), COMPETE2020, Lisboa, Portugal
- Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), Ministry of Education, Culture, Sports, Science, and Technology of Japan, Tokyo, Japan
- Project of Science and Technology Research Program in Fujian Province, P.R. China
- Quadro de Referência Estratégica Nacional (QREN), Lisbon, Portugal
- Red Temática Fermoquímicos CONACYT, Mexico City, Mexico

- Region Örebro läns Forskningskommitté, Örebro, Sweden
 Region Skåne Research Funds, Skåne, Sweden
 Regional Agreement on Medical Training and Clinical Research (ALF), Stockholm County Council and Karolinska Institute, Stockholm, Sweden
 Regione Sicilia, Piano Sanitario Nazionale, Palermo, Italy
 Republic of Croatia
 Republic of Serbia
 Research & Development Operational Programme, European Regional Development Fund (ERDF), Brussels, Belgium
 Research Base Construction Fund Support Program, Chonbuk National University, Jeonju, Republic of Korea
 Research Council of Lithuania, Vilnius, Lithuania
 Research, Development and Innovation Center of Tampere University Hospital, Tampere, Finland
 Research Education Fund, Tokyo University of Science, Tokyo, Japan
 Research Foundation – Flanders (FWO), Brussels, Belgium
 Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
 Research Fund of Tung's Taichung MetroHarbor Hospital, Taichung, Taiwan, R.O.C.
 Research Grants, Royal Physiographic Society, Lund, Sweden
 Research Institute for Veterinary Science, Seoul National University (SNU), Seoul, Republic of Korea
 Research Institute, Moffitt Cancer Center, Tampa, FL, U.S.A.
 Research Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand
 Research Project for Young Scientists, Wroclaw Medical University, Wroclaw, Poland
 Research Service of the Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, U.S.A.
 Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL, U.S.A.
 Roche Farma S.A., Madrid, Spain
 Russian Foundation for Basic Research (RFBR)
 Ryhov Hospital, Jönköping, Sweden
 Ryota Funakoshi Foundation, Columbia University, New York, NY, U.S.A.
- S&P GmbH, Lengenfeld, Germany
 Safety Monitoring Committee, Japan
 Sahlgrenska Academy, University of Gothenburg/Region Västra Götaland, Gothenburg, Sweden
 Saint Mary's Hospital Luodong, Luodong, Taiwan, R.O.C.
- Saitama Medical University International Medical Center, Saitama, Japan
 Saitama Medical University, Saitama, Japan
 Saitama Prefectural University, Saitama, Japan
 Sapporo Medical University, Sapporo, Japan
 Saudi Arabian Cultural Mission (SACM), Fairfax, VA, U.S.A.
 Schaller Research Group, University of Heidelberg, Heidelberg, Germany
 Scholarship for Young/Women Researchers, Promotion and Mutual Aid Corporation for Private Schools of Japan (PMAC), Japan
 School of Allied Health Science, Kitasato University, Sagamihara, Japan
 School of Medicine, Kitasato University, Sagamihara, Japan
 School of Medicine, Toho University, Tokyo, Japan
 School of Pharmacy, Massachusetts College of Pharmacy and Health Science (MCPHS), Boston, MA, U.S.A.
 Science and Technology Programme of Guangzhou, Guangzhou, P.R. China
 Science Foundation Ireland, Dublin, Republic of Ireland
 Scientific and Technical Research Center, Centre de Recherche Scientifique et Technique en Analyses Physico-chimiques (C.R.A.P.C), Tipaza, Algeria
 Scientific and Technological Research Council of Turkey (TUBITAK), Ankara, Turkey
 Scientific Research Commission (CIC), Buenos Aires, Argentina
 Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
 Secretariat of Public Education of Mexico (SEP), Mexico City, Mexico
 Seoul Metropolitan Government (SMG) - Seoul National University (SNU) Boramae Medical Center, Seoul, Republic of Korea
 Seoul National University Hospital (SNUH) Research Fund, Seoul, Republic of Korea
 Seppo Nieminen's Fund, Finland
 Setsuro Fujii Memorial, Japan
 Shanghai Key Specialty Construction Project, P.R. China
 Shanghai Ninth People's Hospital Lin+ Program, Shanghai, P.R. China
 Shanghai Science and Technology Commission, P.R. China
 Shannonvale Hatchery, Cork, Republic of Ireland
 Sigrud Juselius Foundation, Helsinki, Finland
 Site de Recherche Intégrée sur le Cancer (SiRIC), Marseille, France
 Skåne University Hospital Research Foundation, Lund, Sweden

- Slovak Research and Development Agency (SRDA), Bratislava, Slovak Republic
- Smoking Research Foundation, Japan
- Society for Immunotherapy of Cancer, Milwaukee, WI, U.S.A.
- Soonchunhyang University Research Fund, Asan, Republic of Korea
- South Carolina IDeA Networks of Biomedical Research Excellence (SC-INBRE), Rock Hill, SC, U.S.A.
- South Regional Cancer Registry (ROR-SUL), Lisbon, Portugal
- St. Luke's Mountain States Tumor and Medical Research Institute (MSTMRI), Boise, ID, U.S.A.
- Stanford Prevention Research Center, Stanford, CA, U.S.A.
- Startup Foundation for Doctors of Shanxi Medical University, Shanxi, P.R. China
- State Research Funding of Turku, Finland
- Statutory Funds, Wroclaw Medical University, Wroclaw, Poland
- StemScientific, Bristol-Myers Squibb S.A., New York, NY, U.S.A.
- Stiftelsen Gävle Cancerfond, Sandviken, Sweden
- Stiftung Integrative Medizin, Stuttgart, Germany
- Stimulating Peripheral Activity to Relieve Conditions (SPARC), National Institutes of Health, Bethesda, MD, U.S.A.
- Strategic Research Foundation at Private Universities, Ministry of Education, Culture, Sports, Science and Technology of Japan, Japan
- Support Center for Advanced Medical Science, Institute of Biomedical Sciences, Graduate School of Tokushima University, Tokushima, Japan
- Swedish Cancer Foundation, Stockholm, Sweden
- Swedish Cancer Society (Cancerfonden), Stockholm, Sweden
- Swedish Dental Society, Stockholm, Sweden
- Swedish Radiation Safety Authority, Stockholm, Sweden
- Swedish Research Council (Vetenskapsrådet), Stockholm, Sweden
- Swedish Society of Medicine (Bengt Ihre grant), Stockholm, Sweden
- Syngen Biotech, Wroclaw, Poland
- Szeged Foundation for Cancer Research, Szeged, Hungary
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
- Taipei Veterans General Hospital, Taipei City, Taiwan R.O.C.
- Takeda Science Foundation, Japan
- Talents Program of Jiangsu Cancer Hospital, Nanjing, P.R. China
- Tampere University Hospitals, Tampere, Finland
- Tamura Science and Technology Foundation, Japan
- Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C.
- Technological Incubation Program (TIP), University of Connecticut, Storrs, CT, U.S.A.
- Terry Fox Cancer Research Lab, Taipei, Taiwan, R.O.C.
- The Ohio State University, Columbus, OH, U.S.A.
- Thelma Mäkikyrö Foundation, Finland
- Tissue Bank, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C.
- Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
- Tohoku University, Sendai, Japan
- Tokushima University Graduate School, Tokushima, Japan
- Tokyo University of Science, Tokyo, Japan
- Toyo University, Tokyo, Japan
- Translational Research Network Program, Japan Agency for Medical Research and Development, Tokyo, Japan
- Trinity College Dublin, Dublin, Ireland
- TUA Research Funding, Sweden
- Tumour Center at Hannover Medical School, Hannover, Germany
- UConn Innovation Fund, University of Connecticut, Storrs, CT, U.S.A.
- Uehara Memorial Foundation, Taisho Pharmaceutical, Tokyo, Japan
- Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea
- UMAS Cancer Foundation, Boston, MA, U.S.A.
- Uned, Pamplona, Spain
- Unité de Nutrition Humaine (UNH), France
- United States Department of Agriculture (USDA), Agricultural Research Service (ARS), Washington, DC, U.S.A.
- Universidad Nacional del Sur, Bahía Blanca, Argentina
- Université Clermont Auvergne, Equipe ECREIN (France), Clermont-Ferrand, France
- University at Buffalo, Buffalo, NY, U.S.A.
- University Hospital in Pilsen – FNPI, Pilsen, Czech Republic
- University Hospital of Oulu, Oulu, Finland
- University Hospital Ostrava, Ostrava, Czech Republic
- University of Arizona, Tucson/Phoenix, AZ, U.S.A.
- University of Aveiro, Aveiro, Portugal

- University of Florence, Florence, Italy
University of Florida, Gainesville/Jacksonville, FL, U.S.A.
University of Iowa, Iowa City/Davenport, IA, U.S.A.
University of Milan, Milan, Italy
University of Northumbria in Newcastle upon Tyne (UNN) Start-up Fund (MIP), Newcastle Upon Tyne, U.K.
University of Pittsburgh, Pittsburgh, PA, U.S.A.
University of Rochester, Rochester, NY, U.S.A.
University of Rome La Sapienza, Rome, Italy
University of Szeged, Szeged, Hungary
University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.
University of Virginia Health System, Charlottesville, VA, U.S.A.
USC School of Medicine Research and Development Fund, University of South Carolina, Columbia, SC, U.S.A.
USC School of Medicine Research Program for Medical Students, University of South Carolina, Columbia, SC, U.S.A.
USC Science Undergraduate Research Fellowship, University of South Carolina, Columbia, SC, U.S.A.
VA Medical Center Media Service, Minneapolis, MN, U.S.A.
Väisänen Foundation, Finland
Verein für Tumorforschung, Austria
Vietnam National Foundation for Science and Technology Development (NAFOSTED), Hanoi, Vietnam
Vriendtjes Tegen Kanker Fund, Belgium
VUMC Cancer Center Amsterdam (CCA) Foundation, Amsterdam, the Netherlands
Wake Forest University School of Medicine, Winston-Salem, NC, U.S.A.
Warsaw University of Technology, Warsaw, Poland
Welfare Clinical Trial and Research Center of Excellence, Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
WntResearch, Malmö, Sweden
Worldwide Cancer Research, Edinburgh, Scotland
Wroclaw Medical University, Wroclaw, Poland
Wroclaw Research Centre EIT+, Wroclaw, Poland
Wroclaw University of Science and Technology, Wroclaw, Poland
XPE Pharma & Science, Wavre, Belgium
Yonsei University College of Medicine, Seoul, Republic of Korea
Yonsei University, Seoul, Republic of Korea
Yujeonja-Donguibogam Project, Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea
Zuoying Branch, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.

Instructions for Authors 2020

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
 7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
 8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
 9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 66%).
 10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
 11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
 12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
 13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2020 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Review